

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial

Rakesh Popat,¹ Dana Warcel,¹ Jenny O'Nions,¹ Anna Cowley,¹ Sasha Smith,¹ William R Tucker,² Kwee Yong¹ and Simona Degli Esposti²

¹National Institute for Health Research Clinical Research Facility, University College London Hospitals NHS Foundation Trust and ²National Institute for Health Research Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital NHS Foundation Trust & University College London Institute of Ophthalmology, London, UK

Correspondence: RAKESH POPAT - rakesh.popat@ucl.ac.uk

doi:10.3324/haematol.2019.235937

Characterisation of Response and Corneal Events with Extended follow-up after Belantamab Mafodotin (GSK2857916) Monotherapy for Patients with Relapsed Multiple Myeloma: A Case Series from the First-time-in-Human Clinical Trial

Authors: Rakesh Popat, Dana Warcel, Jenny O’Nions, Anna Cowley, Sasha Smith, William R Tucker, Kwee Yong and Simona Degli Esposti

Supplementary Text, table 1: Baseline Demographics

Parameter	Subject					Median
	1	2	3	4	5	
Age/ years	51	51	57	57	66	57
Cytogenetics	1q amp; del 13; t(11;14)	Unk	1q amp; t(11;14)	1q amp; t(11;14)	17p-, unidentified IgG rearrangement	
ISS	2	1	1	1	2	1
Prior Lines	4	4	6	3	3	4
Prior therapies	1.CTD&ASCT: VGPR 2. KCd: PR 3. Rd: PR 4. PVd: PR	1. CD & RTY 2. PAD & ASCT: CR 3. Rd: PR 4. Dara: refractory	1. CTD & ASCT 2. Vd: PR 3. Vd: PR 4. Rd: MR 5. VTD-P: PR 6. Pd: PR	1. PAD: VGPR 2. VTD, ASCT: 3. KCd: PR	1. VCD: MR 2. VTD&ASCT: PR 3. KCd: PR	
PI/ IMiD Refractory?	Both	IMiD refractory	IMiD refractory	PI refractory	PI refractory	
Time from Diagnosis to treatment/ years	3.8	3.8	13.0	3.4	2.7	3.8

PI: proteasome inhibitor; IMiD: immunomodulatory drug; CTD: cyclophosphamide thalidomide dexamethasone; ASCT: autologous stem cell transplant; KCd: Carfilzomib cyclophosphamide dexamethasone; Rd: Lenalidomide dexamethasone; PVd: Pomalidomide, bortezomib, dexamethasone; CD: cyclophosphamide dexamethasone; RTY: radiotherapy; PAD: bortezomib doxorubicin dexamethasone; Dara: daratumumab; Vd: bortezomib dexamethasone; VTD-P: bortezomib thalidomide dexamethasone panobinostat; Pd: pomalidomide dexamethasone; VCD: bortezomib cyclophosphamide dexamethasone; MR: minor response; PR: partial response; VGPR: very good partial response; CR: complete response